The global Morphine, buprenorphine, and other drugs market size was valued at USD 7,700 million in 2021 and is projected to reach around USD 12,500 million in 2030 exhibiting a CAGR of 5.2% in the forecasted period. The growing approval of drugs for opioid addiction treatment is projected to increase the market growth. Additionally, increasing advanced work practices by scholarly foundations will support in creating profitable openings for important market players. For instance, in April 2018, Stanford University Bioengineers adopted another anticancer medication and hack suppressant medication noscapine by added technique for construction in light of maturation of catalysts developed from therapeutic plants, vertebrates, and microorganisms to make the drug. However, overdose of opioids which leads to death, increasing number of litigations that affects the drug approvals will act as a restriction for the growth of this market.

The major drivers backing to the global morphine, buprenorphine and other drug market's growth is the increase in prevalence of diseases such as cancer, arthritis, chronic pain, and fibromyalgia. Numerous narcotic drugs are endorsed for the management of moderate to severe pain in cancer patients. For instance, according to Centers for Disease Control and Prevention (CDC) cancer is among the leading causes of deaths in the U.S. Moreover, as per the U.S. Cancer Statistics of 2021 in 2018 1,708,923 Americans were detected with cancer. Thus, due to prevalence of cancer and use of opioids for treatment of cancer is projected to drive the market growth.

Coronavirus has impacted the economy in after ways; originally by influencing establishment and demand, then, by creating worsening in distribution channels, and in conclusion over the monetary effect on financial markets and firms. Due to lockdowns across the world, India, Saudi Arabia, China, Egypt, UAE, and others are dealing with issues regarding the transportation of opioid drugs.
Additionally, disease patients can’t visit hospitals for the management of opioid treatment due to lockdowns and COVID-19 restrictions which is further restraining the market development. Consequently, morphine, buprenorphine, and other drugs market is unfavourably impacted due to the COVID-19 pandemic.

Besides, the turn of actions and send-off of opioid drugs is depended upon to help with the growth of the global morphine, buprenorphine, and other drugs market. For instance, in March 2019, Piramal Critical Care sent off the Morphine Sulfate infusion in the U.S. with the brand name of Mitigo used for obstinate ongoing pain cure. Morphine Sulfate infusion is consumed for getting moderate grave pain. It is considerably used for pain associated with a myocardial infarction, medical procedure, and malignant development. Therefore, such send-off of new substances is relied upon to boost the morphine, buprenorphine, and other drugs market.

Drug Insights
Among drugs, buprenorphine fragment is relied upon to have the most noteworthy CAGR for the morphine, buprenorphine, and other drugs market during conjecture period, attributable to innovative work and use of buprenorphine along with other drugs for opioid dependence treatment. For instance, WHO has proposed the scope of treatment choices to the patients for opioid reliance. These incorporate opioids for agonist maintenance treatment, pharmacological treatment with bad guy opioids. WHO upholds countries in working on the quality and inclusion of projects for treatment for opioid dependence and giving them where they don’t as of now exist as of which morphine, buprenorphine, and other drugs market is depending upon to grow quickly.

Application Insights
Based on application, the pain management portion is depended upon to show the most notable CAGR attributable to use of opioids for malignant growth pain, myocardial infraction medical procedure, and other postsurgical pain and continuing pain management.

Route of Administration Insights
Based on the route of administration, the oral section signified the most important market share attributable to the relief of the use of the patients. Oral opioids are generally permitted for hack and looseness of the bowels. More opioids are also used for pain management and malignant growth handling and along these lines attributable to most remarkable market share in morphine, buprenorphine, and other drugs market.

Distribution Channel Insights
Based on distribution channels, the hospital pharmacies section is evaluated to stand firm on a dominant foothold in the morphine, buprenorphine, and other drugs market during the figure time frame. Moreover, the rise in hospital assertion of patients undergoing persistent pain and disease is depending on upon to lean concerning the development of the hospital pharmacies fragment over the projected time frame.

Region Insights
Amongst the regions, the North American region characterized the major market share in morphine, buprenorphine, and other drugs markets in 2021. As of late opioids, for instance, buprenorphine is to a great extent used in the U.S. for opioid use problem treatment, hence morphine, buprenorphine, and other drugs market have signified the biggest market share.
However, Asia Pacific is expected to witness the fastest growth rate during the forecasted period. The factors that are anticipated to grow the market are increasing chronic diseases across the region.

Key Companies Insights
The market for Morphine, buprenorphine, and other drugs is moderately competitive. With the rising applications of Morphine, buprenorphine, and other drugs, new players are considering to enter the market. The companies are also involved in activities like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Morphine, buprenorphine, and other drugs market, ultimately boosting the market growth. 

Some of the key companies working in the global Morphine, buprenorphine, and other drugs market include:
• Purdue Pharma
• Sun Pharmaceuticals
• Pfizer Inc.
• West Ward Pharmaceuticals
• Teva Pharmaceuticals
• Piramal Pharmaceuticals
• Hikama Pharmaceuticals
• Indivior PLC
• Oreoxo AB
• Camurus AB
• Novartis
• Other players

Some of the Recent Developments:
• In February 2019, Sandoz (Novartis division) affirmed marketing approval for the nonexclusive SUBOXONE 1 that is a combination of naloxone and buprenorphine, to be available in several measurement qualities in the U.S. The drug is displayed for the treatment of opioid reliance.
• In March 2019, Piramal Critical Care sent off the Morphine Sulfate infusion in the U.S. with the brand name of Mitigo used for obstinate ongoing pain treatment. Morphine Sulfate infusion is utilized for getting modest serious pain.

Segments
By Drug
• Morphine
• Buprenorphine
• Noscapine
• Thebaine
• Etrophine

By Route of Administration
• Oral
• Injectable
• Transdermal

By Application
• Pain Management
• Opioid Addiction Treatment
• Others

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Others

By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt